ZIOP ZIOPHARM Oncology Inc.

Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April

Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April

HOUSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that company management will be participating in the following upcoming investor conferences.

Cantor's The Future of Oncology Virtual Symposium

Date: Tuesday, April 4, 2023

Format: Fireside Chat and 1x1 Meetings

Location: Virtual

22nd Annual Needham Virtual Healthcare Conference

Date: Monday, April 17, 2023

Format: Company Presentation and 1x1 Meetings

Location: Virtual

A live webcast of the Needham presentation will be accessible on the Company’s website in the Investors section under Events & Presentations at A replay of the webcast will be available on the Alaunos website for approximately 90 days following the presentation.

About Alaunos Therapeutics

Alaunos Therapeutics is a leader in the science of T-cell receptor cell therapy working to revolutionize solid cancer treatment and outcomes. The clinical-stage company’s TCR T-cell therapy (TCR-T) is one of the most advanced TCR programs targeting driver mutations in solid tumors with an ongoing Phase 1/2 trial of its TCR-T product candidates across six solid cancers. Alaunos is powered by two proprietary platforms: its elegantly efficient non-viral Sleeping Beauty cell engineering platform; and its hunTR® discovery platform, which is expanding its industry-leading library of TCRs against high-frequency driver mutations. Alaunos is a part of an ongoing collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), working to advance the science of TCR therapy. For more information, visit .

Investor Relations Contact:

Alex Lobo

Stern Investor Relations

Media Contact:

Heather Anderson

6 Degrees PR



EN
29/03/2023

Underlying

ZIOPZIOPHARM Oncology Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ZIOPHARM Oncology Inc.

 PRESS RELEASE
Free
ZIOP ZIOPHARM Oncolo...

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, P...

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patientshunTR® discovered new HLA class I and class II restricted TCRs that recognize driver mutations, including KRAS and TP53Company continues to explore potential strategic alternatives; cost-savings measures expected to extend cash runaway into the second quar...

November 14, 2023 1 EN
 PRESS RELEASE
Free
ZIOP ZIOPHARM Oncolo...

Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, ...

Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patientsCompany to wind down TCR-T Library Phase 1/2 trial and concurrently explore potential partnering opportunities for the hunTR® platform as well as broad strategic alternativesReducing headcount by approximately 60% while retaining key hunTR® R&D capabilities HOUS...

August 14, 2023 1 EN
 PRESS RELEASE
Free
ZIOP ZIOPHARM Oncolo...

Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global S...

Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Company will present at the 2nd Hawaii Global Summit on Thoracic Malignancies taking place June 27 – July 1, 2023. Alaunos Director of Translational Sciences Matthew Collinson-Pautz, Ph.D., will discuss the Company’s TCR-T therapy...

June 29, 2023 1 EN
 PRESS RELEASE
Free
ZIOP ZIOPHARM Oncolo...

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/...

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting TCR-T cell therapy shows first-in-human response for non-viral TCR-T therapy; effectively targets high frequency TP53 and KRAS driver mutations across multiple solid tumor indicationsTreatment was well tolerated with a manageable safety profile and persistence of TCR-T cells in peripheral blood observed in all three treated patients at last follow-upProof-of-concept demonstrated for non-viral Sleeping Beauty cell engineering platform in effective manufa...

May 25, 2023 1 EN
 PRESS RELEASE
Free
ZIOP ZIOPHARM Oncolo...

Alaunos Therapeutics Reports First Quarter 2023 Financial Results

Alaunos Therapeutics Reports First Quarter 2023 Financial Results Actively enrolling patients and manufacturing cryopreserved products for TCR-T Library Phase 1/2 trial; expect to report interim data in the third quarter of 2023Fully prepaid loan with Silicon Valley Bank; now a debt-free companyAmended exclusive licensing agreement with Precigen, Inc., reflecting the Company’s focus on its TCR-T programs and eliminating long-term financial obligationsCompany to host conference call today at 9:00 a.m. ET HOUSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” o...

May 10, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch